You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The firm has filed for CE marking for the initial MosaiQ IH microarray and anticipates filing for its first serological disease screening microarray during the first half of 2019.
The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The ID Core XT is the second molecular assay approved by the FDA for use in transfusion medicine and the first to report genotypes as final results.
In an email, the company's CEO said it is running out of funds and has been unable to find new investors — the shutdown could start on Sept. 10.
The test can be used on donated blood samples as well as other human cells and tissues.
With the NeoLSD MSMS kit, labs can leverage tandem mass spec technology, which reduces sample prep and analysis times, to run hundreds of tests per day.
A combined assay to screen blood donations for HIV and hepatitis viruses and a test for West Nile virus are now cleared to run on the Procleix Panther system.